Novartis decides not to make offer to acquire Berna Biotech
Basel, January 10, 2006 - After completion of due diligence and an assessment of the potential benefits and risks of an acquisition, Novartis has decided not to make an offer for Berna Biotech AG.
Novartis announced in December that it was considering whether to acquire Berna Biotech AG after Crucell N.V., a Dutch biotechnology company, made an offer earlier in December to acquire the Swiss company through an all-share exchange offer.
Novartis AG (NYSE: NVS) is a world leader in pharmaceuticals and consumer health. In 2004, the Groupís businesses achieved net sales of USD 28.2 billion and pro forma net income of USD 5.6 billion. The Group invested approximately USD 4.1 billion in R&D. Headquartered in Basel, Switzerland, Novartis Group companies employ about 91,700 people and operate in over 140 countries around the world.
For further information please consult http://www.novartis.com.
- Contact Information
- John Gilardi
- Novartis Global Media Relations
- Novartis AG
- Contact via E-mail
This news content was configured by WebWire editorial staff. Linking is permitted.
News Release Distribution and Press Release Distribution Services Provided by WebWire.